PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer

被引：7

作者：

Eroglu, A

Çam, R

Yildiz, Z

Akar, N

机构：

[1] Ankara Univ, Sch Med, Breast Surg Unit, Dept Gen Surg, Ankara, Turkey

[2] Ankara Univ, Sch Med, Dept Pediat Mol Genet, Ankara, Turkey

来源：

THROMBOSIS RESEARCH | 2003年 / 111卷 / 4-5期

关键词：

D O I：

10.1016/j.thromres.2003.09.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：317 / 319

页数：3

共 25 条

[1]

Akar N, 1997, THROMB HAEMOSTASIS, V78, P1527

[2]

Akar N, 2000, AM J HEMATOL, V63, P102, DOI 10.1002/(SICI)1096-8652(200002)63:2<102::AID-AJH10>3.0.CO

[3]

2-R

[4]

Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P193

[5] HIGH PREVALENCE OF A MUTATION IN THE FACTOR-V GENE WITHIN THE UK POPULATION - RELATIONSHIP TO ACTIVATED PROTEIN-C RESISTANCE AND FAMILIAL THROMBOSIS [J].

BEAUCHAMP, NJ ;

DALY, ME ;

HAMPTON, KK ;

COOPER, PC ;

PRESTON, FE ;

PEAKE, IR .

BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (01) :219-222

[6] MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].

BERTINA, RM ;

KOELEMAN, BPC ;

KOSTER, T ;

ROSENDAAL, FR ;

DIRVEN, RJ ;

DERONDE, H ;

VANDERVELDEN, PA ;

REITSMA, PH .

NATURE, 1994, 369 (6475) :64-67

[7] Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V leiden) and His1299Arg substitutions in factor V [J].

Castaman, G ;

Lunghi, B ;

Missiaglia, E ;

Bernardi, F ;

Rodeghiero, F .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (02) :257-261

[8]

DAHLBACK B, 1995, THROMB HAEMOSTASIS, V74, P139

[9] Epidemiology of factor V Leiden: Clinical implications [J].

De Stefano, V ;

Chiusolo, P ;

Paciaroni, K ;

Leone, G .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (04) :367-379

[10]

DOLL DC, 1992, SEMIN ONCOL, V19, P580

← 1 2 3 →